This study is a multi-center, retrospective observational study of patients with lung NUT carcinoma. Existing clinical records from participating hospitals will be reviewed to describe patient characteristics, treatments, and outcomes. No study-related interventions will be performed. Data will be de-identified to protect patient privacy.
This is a multi-center, retrospective observational cohort study of lung NUT carcinoma. Eligible patients diagnosed with lung NUT carcinoma at participating hospitals will be identified based on pathology with supportive evidence of NUT immunohistochemistry (IHC) positivity and/or NUTM1 rearrangement/fusion. Data will be extracted from existing medical records and follow-up documentation, including demographics, tumor characteristics, staging, treatments, and outcomes. When available, routine-care pathology information and imaging data will be collected and de-identified. Primary outcome: progression-free survival (PFS). Secondary outcomes: overall survival (OS) and other routinely documented outcomes when available. No new drugs, devices, procedures, or additional tests will be provided as part of this research. All data will be de-identified and stored with access controls according to applicable regulations and ethics approvals at each participating site.
Study Type
OBSERVATIONAL
Enrollment
150
Treatments received as part of routine clinical care and recorded retrospectively in medical records, which may include surgery, radiotherapy, systemic chemotherapy, targeted therapy, and/or immunotherapy. No study-related intervention will be assigned or provided. This observational study only collects and analyzes de-identified real-world treatment and outcome data.
Chongqing University Three Gorges Hospital
Chongqing, Chongqing Municipality, China
Progression-Free Survival (PFS)
Time from initial diagnosis (index date) to first documented disease progression per routine clinical assessment or death from any cause, whichever occurs first.
Time frame: From diagnosis through study completion (up to May 2026)
Overall Survival (OS)
Time from initial diagnosis (index date) to death from any cause.
Time frame: From diagnosis through study completion (up to May 2026)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.